Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients - PARLIM

Trial Profile

Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients - PARLIM

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARLIM
  • Most Recent Events

    • 17 Oct 2011 EudraCT identified as an additional source, and additional EudraCT identifier and study acronym added
    • 17 Oct 2011 Status changed from not yet recruiting to recruiting.
    • 01 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top